Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 7712345...102030...Last »

Versartis Growth Hormone Drug Fails Phase III Test

Versartis Inc. said the company’s experimental human growth hormone somavaratan failed to meet endpoints in a critical Phase III trial.

Read More »

Alnylam Genetic Disease Drug Meets Study Goals

Positive Phase III data were reported for Alnylam’s RNA interference treatment for hereditary ATTR amyloidosis with polyneuropathy.

Read More »

Nabriva’s pneumonia drug succeeds in late-stage trial

Nabriva Therapeutics’ experimental antibiotic lefamulin for CABP met the main goal of a late-stage study.

Read More »

Prostate cancer drug clears late-stage trial

Pfizer Inc. and Astellas Pharma Inc. said their drug to treat a type of prostate cancer met the main goal of improving overall survival in a late-stage trial.

Read More »

Amicus Ends Lead Rare Disease Drug Program

Amicus Therapeutics terminated a late-stage wound-treatment therapeutic after it failed to meet primary and secondary endpoints in a Phase III trial.

Read More »

Vertex Ends Phase II CF Trial

Vertex Pharmaceuticals reportedly terminated a long-acting trial combining a recently acquired therapy with the company’s cystic fibrosis drug Kalydeco.

Read More »

Sage’s seizure drug fails key trial

Sage Therapeutics Inc.’s shares tumbled 23 percent after its drug to treat a life-threatening seizure disorder failed to meet the main goal of a key trial.

Read More »

New Shire drug significantly reduces HAE attacks

London-listed drugmaker Shire successfully tested a new medicine that prevents attacks in patients with hereditary angioedema (HAE).

Read More »

Two Deaths Hit AbbVie’s Late-Stage RA Study

AbbVie announced positive top-line results from its Phase III clinical trial of upadacitinib (ABT-494) in moderate-to-severe rheumatoid arthritis patients.

Read More »

Driving Global Clinical Trial Success: Four Top Strategies

The pharma landscape has significantly evolved in the last decade, especially when it comes to clinical trials.

Read More »

After melanoma surgery, Bristol’s Opdivo offers new care standard

Bristol-Myers Squibb’s immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients who have had surgery to remove disease, researchers reported.

Read More »

AstraZeneca rebuilds cancer drug hopes with new lung data

Two AstraZeneca drugs tackling lung cancer in different ways delivered impressive clinical results on Saturday, helping the British group offset July 2017’s big clinical trial setback in the disease.

Read More »

Death puts Cellectis cell therapy tests on hold

French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment, was forced to suspend testing following a patient death.

Read More »

Otonomy pulls plug on ear drug, shares nosedive

Otonomy Inc. suspended developing its drug for Meniere’s disease, a chronic disorder of the inner ear, after it failed a late-stage trial.

Read More »

A First: Novartis AG Drug May Prevent Heart Attacks and Cut Lung Cancer Risk Too

An anti-inflammatory drug developed for cardiac patients has an exciting, yet unintended side effect – possible prevention of lung cancer.

Read More »

Vision loss associated with cognitive decline, dementia

Hearing impairment is already linked to a heightened risk of cognitive decline in old age, and a new study suggests that impaired vision may carry the same risk.

Read More »

Muscle Disease Drug Development Halted

A Phase 3 study evaluating Ultragenyx Pharmaceuticals’ aceneuramic acid extended release in patients with GNE Myopathy did not achieve its primary endpoint.

Read More »

Novo Nordisk’s semaglutide beats out Trulicity

Positive results were announced from Novo Nordisk’s SUSTAIN 7 Phase III trial comparing once-weekly semaglutide against Lilly’s Trulicity for type 2 diabetes.

Read More »

Bristol-Myers Kidney Cancer Drug Flunks Study

Bristol-Myers Squibb released mixed top-line results from its Phase III CheckMate-214 clinical trial of Opdivo in combination with Yervoy for advanced or metastatic RCC.

Read More »

Lexicon Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin

Lexicon Pharmaceuticals Inc. announced additional positive data from the pivotal Phase 3 inTandem2 study of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor.

Read More »

Page 1 of 7712345...102030...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2017 Focus: Pharma Innovators, Top 200 Meds, Lions Health and more!

Subscribe

Ad Right Bottom

Main Navigation